ADENOCOR INJECTION 3MGML

Χώρα: Σιγκαπούρη

Γλώσσα: Αγγλικά

Πηγή: HSA (Health Sciences Authority)

Δραστική ουσία:

ADENOSINE

Διαθέσιμο από:

SANOFI-AVENTIS SINGAPORE PTE. LTD.

Φαρμακολογική κατηγορία (ATC):

C01EB10

Δοσολογία:

6.0mg/2 ml

Φαρμακοτεχνική μορφή:

INJECTION

Σύνθεση:

ADENOSINE 6.0mg/2 ml

Οδός χορήγησης:

INTRAVENOUS

Τρόπος διάθεσης:

Prescription Only

Κατασκευάζεται από:

Famar Health Care Services Madrid, S.A.U.

Καθεστώς αδειοδότησης:

ACTIVE

Ημερομηνία της άδειας:

1994-04-05

Φύλλο οδηγιών χρήσης

ADENOCOR 
_Adenosine _
SOLUTION FOR INJECTION 
[SANOFI LOGO] 

1.  TRADE NAME OF MEDICINAL PRODUCT 
Adenocor 

2.  QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each vial contains 6 mg of adenosine per 2 ml (3 mg/ml) 
For excipients, see 6.1 

3. PHARMACEUTICAL 
FORM 
Solution for injection 
Clear, colourless solution 

4. CLINICAL 
PARTICULARS 
4.1 Therapeutic Indications  
Rapid conversion to a normal sinus rhythm of paroxysmal
supraventricular tachycardias, including 
those associated with accessory by-pass tracts (Wolff-Parkinson-White
Syndrome).  
Diagnostic Indications  
Aid to diagnosis of broad or narrow complex supraventricular
tachycardias. Although Adenocor will 
not convert atrial flutter, atrial fibrillation or ventricular
tachycardia to sinus rhythm, the slowing of AV 
conduction helps diagnosis of atrial activity.  
Sensitisation of intra-cavitary electrophysiological
investigations. 

4.2 Posology and Method of Administration  
Adenocor is intended for hospital use only with monitoring and
cardiorespiratory resuscitation 
equipment available for immediate use. It
should be administered by rapid IV bolus injection 
according to the ascending dosage schedule below. To be certain
the solution reaches the systemic 
circulation administer either directly into a vein or into an IV
line. If given into an IV line it should be 
injected as proximally as possible, and followed by a rapid saline
flush.  
Adenocor should only be used when facilities exist for cardiac
monitoring. Patients who develop high-
level AV block at a particular dose should not be given further dosage
increments.  
THERAPEUTIC DOSE  
Adult:  
Initial dose: 3 mg given as a rapid intravenous bolus (over 2
seconds).  
Second dose: If the first dose does not result in elimination of
the supraventricular tachycardia within 
1 to 2 minutes, 6 mg should be given also as a rapid intravenous
bolus.  
Third dose: If the second dose does not re

Αρχείο Π.Χ.Π.

ADENOCOR
_Adenosine _
SOLUTION FOR INJECTION
[SANOFI LOGO]
1.
TRADE NAME OF MEDICINAL PRODUCT
Adenocor
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 6 mg of adenosine per 2 ml (3 mg/ml)
For excipients, see 6.1
3.
PHARMACEUTICAL FORM
Solution for injection
Clear, colourless solution
4.
CLINICAL PARTICULARS
4.1 Therapeutic Indications
Rapid conversion to a normal sinus rhythm of paroxysmal
supraventricular tachycardias, including
those associated with accessory by-pass tracts (Wolff-Parkinson-White
Syndrome).
Diagnostic Indications
Aid to diagnosis of broad or narrow complex supraventricular
tachycardias. Although Adenocor will
not convert atrial flutter, atrial fibrillation or ventricular
tachycardia to sinus rhythm, the slowing of AV
conduction helps diagnosis of atrial activity.
Sensitisation of intra-cavitary electrophysiological investigations.
4.2 Posology and Method of Administration
Adenocor
is intended for hospital use only with monitoring and
cardiorespiratory resuscitation
equipment available for immediate use. It should be administered by
rapid IV bolus injection
according to the ascending dosage schedule below. To be certain the
solution reaches the systemic
circulation administer either directly into a vein or into an IV line.
If given into an IV line it should be
injected as proximally as possible, and followed by a rapid saline
flush.
Adenocor should only be used when facilities exist for cardiac
monitoring. Patients who develop high-
level AV block at a particular dose should not be given further dosage
increments.
THERAPEUTIC DOSE
Adult:
Initial dose: 3 mg given as a rapid intravenous bolus (over 2
seconds).
Second dose: If the first dose does not result in elimination of the
supraventricular tachycardia within
1 to 2 minutes, 6 mg should be given also as a rapid intravenous
bolus.
Third dose: If the second dose does not result in elimination of the
supraventricular tachycardia within
1 to 2 minutes. 12mg should be given also as a rapid intravenous
bolus.
Additional or higher dose